De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: a systematic review of prospective trials
Numerous trials have been launched over the prior decade examining the safety and efficacy of therapy de-escalation in human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). Because no summative assessment of these prospective trials exists to date, we systematically reviewed the outcomes...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
09 March 2020
|
| In: |
Oral oncology
Year: 2020, Jahrgang: 103 |
| ISSN: | 1879-0593 |
| DOI: | 10.1016/j.oraloncology.2020.104608 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.oraloncology.2020.104608 Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S1368837520300440 
|
| Verfasserangaben: | Roshal R. Patel, Ethan B. Ludmir, Alexander Augustyn, Nicholas G. Zaorsky, Eric J. Lehrer, Rohith Ryali, Daniel M. Trifiletti, Sebastian Adeberg, Arya Amini, Vivek Verma |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1695780116 | ||
| 003 | DE-627 | ||
| 005 | 20240405193243.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200423s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.oraloncology.2020.104608 |2 doi | |
| 035 | |a (DE-627)1695780116 | ||
| 035 | |a (DE-599)KXP1695780116 | ||
| 035 | |a (OCoLC)1341316421 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Patel, Roshal R. |e VerfasserIn |0 (DE-588)1208845470 |0 (DE-627)1695780949 |4 aut | |
| 245 | 1 | 0 | |a De-intensification of therapy in human papillomavirus associated oropharyngeal cancer |b a systematic review of prospective trials |c Roshal R. Patel, Ethan B. Ludmir, Alexander Augustyn, Nicholas G. Zaorsky, Eric J. Lehrer, Rohith Ryali, Daniel M. Trifiletti, Sebastian Adeberg, Arya Amini, Vivek Verma |
| 264 | 1 | |c 09 March 2020 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 23.04.2020 | ||
| 520 | |a Numerous trials have been launched over the prior decade examining the safety and efficacy of therapy de-escalation in human papillomavirus (HPV)-associated oropharyngeal cancer (OPC). Because no summative assessment of these prospective trials exists to date, we systematically reviewed the outcomes and toxicities associated with therapy de-intensification for this population. PRISMA-guided systematic PubMed searches (along with articles known to the authors and references thereof) were performed for prospective studies reporting clinical outcomes and/or toxicities of de-intensified RT and/or systemic therapy (with or without surgery), exclusively for HPV-associated OPC. Ten prospective studies were analyzed. Performing a meta-analysis was not entirely possible owing to the heterogeneity of treatment paradigms and the lack of >2 studies for most paradigms; however, because just one paradigm (induction chemotherapy followed by reduced-dose RT and/or systemic therapy) had 4 associated articles, an exploratory meta-analysis was conducted for that subset. Two trials of dose-reduced concurrent chemoradiotherapy (60 Gy/weekly cisplatin) demonstrated 3-year distant metastasis-free survival and overall survival (OS) ranging from 91 to 100% and 95%, respectively; acute grade 3+ mucositis and dysphagia occurred in 33-35% and 21-39%, respectively. In the four trials of induction chemotherapy (platinum/taxane-based) followed by dose-reduced RT, 2-year progression-free and OS ranged from 80 to 95% and 83 to 98%, respectively; acute grade 3+ dysphagia, dermatitis, and mucositis ranged from 9 to 15%, 7 to 20%, and 9 to 30% (excluding one outlier), respectively. For these four trials, the exploratory meta-analysis showed a pooled 2-year PFS and OS of 89% (95% confidence interval, 80-96%) and 96% (92-99%). The pooled rates of grade ≥3 dysphagia, dermatitis, and mucositis were 13% (7-19%), 9% (5-14%), and 28% (9-53%). However, there was significant heterogeneity in the 2-year PFS (I2 = 57%, p = 0.07) and grade ≥3 mucositis (I2 90%, p < 0.01). Next, both randomized trials which replaced concurrent tri-weekly cisplatin with weekly cetuximab illustrated superior outcomes with the former. Lastly, two remaining trials (one using functional imaging to guide reduced-dose RT, and another examining reduced-dose postoperative RT) also showed satisfactory outcomes and toxicities. Taken together, dose-reduced chemoradiotherapy (with or without induction chemotherapy for patient/biology selection purposes) seems to be a promising de-escalation strategy for HPV-associated OPC, although replacement of concurrent cisplatin by cetuximab is not recommended. Long-term follow-up is required for firmer conclusions. | ||
| 650 | 4 | |a De-escalation | |
| 650 | 4 | |a De-intensification | |
| 650 | 4 | |a Head and neck | |
| 650 | 4 | |a HPV positive | |
| 650 | 4 | |a Oropharyngeal | |
| 650 | 4 | |a Radiotherapy | |
| 700 | 1 | |a Ludmir, Ethan B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Augustyn, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaorsky, Nicholas G. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lehrer, Eric J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ryali, Rohith |e VerfasserIn |4 aut | |
| 700 | 1 | |a Trifiletti, Daniel M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Adeberg, Sebastian |d 1984- |e VerfasserIn |0 (DE-588)1049743377 |0 (DE-627)782574467 |0 (DE-576)403727774 |4 aut | |
| 700 | 1 | |a Amini, Arya |e VerfasserIn |4 aut | |
| 700 | 1 | |a Verma, Vivek |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oral oncology |d Amsterdam [u.a.] : Elsevier Science, 1997 |g 103(2020) Artikel-Nummer 104608, 9 Seiten |h Online-Ressource |w (DE-627)320498980 |w (DE-600)2011971-9 |w (DE-576)106869612 |x 1879-0593 |7 nnas |a De-intensification of therapy in human papillomavirus associated oropharyngeal cancer a systematic review of prospective trials |
| 773 | 1 | 8 | |g volume:103 |g year:2020 |g extent:9 |a De-intensification of therapy in human papillomavirus associated oropharyngeal cancer a systematic review of prospective trials |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.oraloncology.2020.104608 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1368837520300440 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200423 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1049743377 |a Adeberg, Sebastian |m 1049743377:Adeberg, Sebastian |d 910000 |d 911400 |d 50000 |e 910000PA1049743377 |e 911400PA1049743377 |e 50000PA1049743377 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1695780116 |e 3631048599 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Roshal R. Patel, Ethan B. Ludmir, Alexander Augustyn, Nicholas G. Zaorsky, Eric J. Lehrer, Rohith Ryali, Daniel M. Trifiletti, Sebastian Adeberg, Arya Amini, Vivek Verma"]},"recId":"1695780116","note":["Gesehen am 23.04.2020"],"person":[{"display":"Patel, Roshal R.","family":"Patel","given":"Roshal R.","role":"aut"},{"display":"Ludmir, Ethan B.","family":"Ludmir","given":"Ethan B.","role":"aut"},{"display":"Augustyn, Alexander","family":"Augustyn","given":"Alexander","role":"aut"},{"role":"aut","given":"Nicholas G.","family":"Zaorsky","display":"Zaorsky, Nicholas G."},{"display":"Lehrer, Eric J.","family":"Lehrer","given":"Eric J.","role":"aut"},{"display":"Ryali, Rohith","family":"Ryali","given":"Rohith","role":"aut"},{"role":"aut","given":"Daniel M.","family":"Trifiletti","display":"Trifiletti, Daniel M."},{"given":"Sebastian","display":"Adeberg, Sebastian","family":"Adeberg","role":"aut"},{"role":"aut","display":"Amini, Arya","family":"Amini","given":"Arya"},{"family":"Verma","display":"Verma, Vivek","given":"Vivek","role":"aut"}],"title":[{"title_sort":"De-intensification of therapy in human papillomavirus associated oropharyngeal cancer","subtitle":"a systematic review of prospective trials","title":"De-intensification of therapy in human papillomavirus associated oropharyngeal cancer"}],"physDesc":[{"extent":"9 S."}],"relHost":[{"origin":[{"dateIssuedDisp":"1997-","publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1997","publisher":"Elsevier Science"}],"id":{"eki":["320498980"],"issn":["1879-0593"],"zdb":["2011971-9"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"part":{"volume":"103","year":"2020","extent":"9","text":"103(2020) Artikel-Nummer 104608, 9 Seiten"},"title":[{"title_sort":"Oral oncology","title":"Oral oncology"}],"physDesc":[{"extent":"Online-Ressource"}],"disp":"De-intensification of therapy in human papillomavirus associated oropharyngeal cancer a systematic review of prospective trialsOral oncology","recId":"320498980","pubHistory":["33.1997 -"],"note":["Gesehen am 31.05.23"]}],"id":{"doi":["10.1016/j.oraloncology.2020.104608"],"eki":["1695780116"]},"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"09 March 2020"}]} | ||
| SRT | |a PATELROSHADEINTENSIF0920 | ||